Nicholas Investment Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Nicholas Investment Partners’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-77,214	Closed	-$4.62M	–	242
2018 Q2	$4.62M	Buy	77,214 +483	+0.6%	+$25K	0.32%	95
2018 Q1	$3.51M	Buy	76,731 +1,635	+2%	+$68.2K	0.25%	132
2017 Q4	$2.99M	Buy	75,096 +1,227	+2%	+$48.5K	0.2%	164
2017 Q3	$2.96M	Buy	+73,869	New	+$3.2M	0.2%	170
2017 Q1	–	Sell	-130,919	Closed	-$3.31M	–	281
2016 Q4	$3.31M	Sell	130,919 -5,857	-4%	-$131K	0.25%	162
2016 Q3	$3.38M	Hold	136,776	–	–	0.22%	179
2016 Q2	$2.79M	Buy	136,776 +6,253	+5%	+$111K	0.19%	219
2016 Q1	$1.99M	Buy	+130,523	New	+$1.7M	0.15%	232

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Nicholas Investment Partners's SUPN Position: Q3 2018 in Review

Nicholas Investment Partners sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 77,214 shares — an estimated $4.62M sold.

Nicholas Investment Partners first reported a position in SUPN in Q1 2016 and held it in 8 quarters. The position peaked at $4.62M in Q2 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

Nicholas Investment Partners reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Nicholas Investment Partners sold 77,214 Supernus Pharmaceuticals shares in Q3 2018, an estimated $4.62M.
Nicholas Investment Partners first reported a position in Supernus Pharmaceuticals in Q1 2016 and held it in 8 quarters.
Nicholas Investment Partners's Supernus Pharmaceuticals position peaked at $4.62M in Q2 2018.
288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on Nicholas Investment Partners's 13F filing for Q3 2018, filed 14 Nov 2018.